Catherine Schnabel

Dr. Catherine Schnabel has over 15 years of experience as an industry scientist across pharmaceutical, clinical and diagnostics research, including positions with Genentech, Genoptix, and Amylin Pharmaceuticals. Joining Biotheranostics in 2009, she has led the translational science and strategic programs for clinical development of proprietary molecular diagnostics in oncology and genomic medicine. Schnabel received her Ph.D. in molecular and cellular biology at the Center for Advanced Biotechnology and Medicine, and was a postdoctoral fellow of the NIH and the Leukemia and Lymphoma Society at Stanford University. Schnabel is an industry leader in the development of evidence-based diagnostics and in building clinical value for molecular tests. She is a named co-inventor on several patents and has authored numerous publications. As Chief Scientific Officer, Dr. Schnabel provides scientific leadership and continued oversight of clinical development, medical strategy, and regulatory plans for Biotheranostics products.